Form 4: Lantern Pharma Director Exercises Warrants, Acquires Common Stock
SEC Form 4
Director D Jeffrey Keyser exercised Series A warrants to purchase 3,832 shares of Lantern Pharma (LTRN) common stock at $3.13 per share.
Summary
- On July 24, 2024, D Jeffrey Keyser, a director of Lantern Pharma Inc. (LTRN), exercised Series A warrants.
- This resulted in the acquisition of 3,832 shares of common stock at an exercise price of $3.13 per share.
- Following the transaction, Keyser directly owns 0 shares of common stock and 0 Series A Warrants.
Sentiment
Score: 5
Explanation: Neutral. This is a routine transaction (warrant exercise) by a company director. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This is a standard SEC Form 4 filing, indicating a change in beneficial ownership by a company insider. It's a routine part of corporate governance and provides transparency to the market.
Stakeholder Impact
- The exercise of warrants slightly increases the number of outstanding shares, which could have a marginal dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 07/25/2019 | Original date of Series A Warrants |
| 07/24/2024 | Date of warrant exercise by D Jeffrey Keyser |
| 07/25/2024 | Expiration date of Series A Warrants |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.